Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Thomas C. Smyrk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6194-7853; OpenAlex author ID A5049580044; NIH RePORTER profile ID 9744987. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
92
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 6 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper, 1 grant · 2019: 3 papers · 2020: 4 papers

Papers 21

  1. Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Co-author DOI 10.1016/j.cgh.2019.07.017↗
  2. Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.011↗
  3. Pancreatic ductal adenocarcinoma is associated with a unique endocrinopathy distinct from type 2 diabetes mellitus. Co-author DOI 10.1016/j.pan.2020.05.010↗
  4. Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. Co-author DOI 10.1016/j.pan.2020.06.015↗
  5. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Co-author DOI 10.1002/jso.25681↗
  6. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Canc… Co-author DOI 10.1038/s41395-018-0403-2↗
  7. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adeno… Co-author DOI 10.1634/theoncologist.2018-0878↗
  8. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. First author DOI 10.1053/j.gastro.2018.04.025↗
  9. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2017.07.007↗
  10. Impact of Intratumoral Inflammation on Survival After Pancreatic Cancer Resection. First author DOI 10.1097/mpa.0000000000000423↗
  11. Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Co-author DOI 10.1136/gutjnl-2014-308350↗
  12. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cance… First author DOI 10.1038/bjc.2014.659↗
  13. Serum IgG4 elevation in pancreatic cancer: diagnostic and prognostic significance and association with autoimmune pancreatitis. Co-author DOI 10.1097/mpa.0000000000000297↗
  14. Transcriptomic and Immunohistochemical Profiling of SLC6A14 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2015/593572↗
  15. Pancreatic Cancer-Derived Exosomes Cause Paraneoplastic β-cell Dysfunction. Co-author DOI 10.1158/1078-0432.ccr-14-2022↗
  16. New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. Co-author DOI 10.1158/1078-0432.ccr-14-2469↗
  17. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  18. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  19. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Co-author DOI 10.1038/oncsis.2013.23↗
  20. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Co-author DOI 10.1053/j.gastro.2012.08.044↗
  21. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Co-author DOI 10.1053/j.gastro.2010.12.039↗

Grants 1

  1. Administrative Core P50CA102701↗

Closest collaborators

The 25 strongest of 92 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Suresh T. Chari · 11 shared papers, 1 shared grant, 2012–2020 · strength 0.94
  2. Gloria M. Petersen · 5 shared papers, 1 shared grant, 2012–2020 · strength 0.40
  3. Martín E. Fernández-Zapico · 4 shared papers, 1 shared grant, 2012–2020 · strength 0.37
  4. Debabrata Mukhopadhyay · 3 shared papers, 1 shared grant, 2012–2018 · strength 0.28
  5. Michael J. Levy · 3 shared papers, 2018–2020 · strength 0.26
  6. Shounak Majumder · 3 shared papers, 2019–2020 · strength 0.26
  7. Daniel D. Billadeau · 3 shared papers, 1 shared grant, 2013–2018 · strength 0.25
  8. Wilma Lingle · 1 shared paper, 1 shared grant, 2018–2020 · strength 0.23
  9. Fergus Joseph Couch · 2 shared papers, 1 shared grant, 2011–2018 · strength 0.22
  10. Ayush Sharma · 2 shared papers, 2018–2020 · strength 0.21
  11. Sajan Jiv Singh Nagpal · 2 shared papers, 2019–2020 · strength 0.18
  12. Naoki Takahashi · 2 shared papers, 2019 · strength 0.17
  13. Michael L. Kendrick · 2 shared papers, 2019 · strength 0.17
  14. George P. Kim · 2 shared papers, 2019–2020 · strength 0.17
  15. Mitesh J. Borad · 2 shared papers, 2020 · strength 0.16
  16. Angela L. McCleary‐Wheeler · 2 shared papers, 2020 · strength 0.16
  17. Ryan Michael Carr · 2 shared papers, 2020 · strength 0.16
  18. Charles Erlichman · 2 shared papers, 2020 · strength 0.16
  19. Tanios Bekaii‐Saab · 2 shared papers, 2020 · strength 0.16
  20. Mark D. Topazian · 2 shared papers, 2019–2020 · strength 0.16
  21. Ferga C. Gleeson · 2 shared papers, 2019–2020 · strength 0.16
  22. Santhi Swaroop Vege · 2 shared papers, 2019–2020 · strength 0.16
  23. Peter A Cohen · 1 shared grant, 2018 · strength 0.15
  24. Eduardo N Chini · 1 shared grant, 2018 · strength 0.15
  25. Pinku Mukherjee · 1 shared grant, 2018 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.